During the past 18 months, numerous clinical trials have reported important findings that impact breast cancer treatment. In two recent articles in The ASCO Post, Jame Abraham, MD, Cleveland Clinic’s Director of Medical Breast Oncology and Co-Director of the Comprehensive Breast Cancer Program, reviews some of the latest research highlights, excerpted from “Breast Cancer Year in Review: 2014 and Beyond.”
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Read the Part 1 review at The ASCO Post
Read the Part 2 review at The ASCO Post
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access
Key learnings from DESTINY trials
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy